Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: Results from the international mrcc database consortium

Clinical Genitourinary Cancer

Volumn 13, Issue 2, 2015, Pages 150-155

  Fay, André P ^a   Xie, Wanling L ^a   Lee, Jae Lyn ^b   Harshman, Lauren C ^a,c   Bjarnason, Georg A ^d   Knox, Jennifer J ^e   Ernst, Scott ^f   Wood, Lori ^g   Vaishamayan, Ulka N ^h   Yuasa, Takeshi ⁱ   Tan, Min Han ^j   Rha, Sun Young ^k   Donskov, Frede ^l   Agarwal, Neeraj ^m   Kollmannsberger, Christian K ⁿ   North, Scott A ^o   Rini, Brian I ^p   Choueiri, Toni K ^a   Heng, Daniel Y C ^q  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c STANFORD CANCER INSTITUTE   (United States)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h KARMANOS CANCER INSTITUTE   (United States)

ⁱ CANCER INSTITUTE HOSPITAL   (Japan)

^j DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^k Yonsei University College of Medicine   (South Korea)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m UNIVERSITY OF UTAH   (United States)

ⁿ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^o CROSS CANCER INSTITUTE   (Canada)

^p TAUSSIG CANCER INSTITUTE   (United States)

^q UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

Long term survival; Overall survival; Primary refractory disease; Prognostic factors; Renal cell carcinoma; Targeted therapies

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT;

ADULT; ADVERSE OUTCOME; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; KIDNEY METASTASIS; LABORATORY TEST; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; OVERALL SURVIVAL; PERSONAL EXPERIENCE; RISK FACTOR; SHORT TERM SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; AGED; CARCINOMA, RENAL CELL; FACTUAL DATABASE; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SURVIVAL; THEORETICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84924350591     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.09.003     Document Type: Article

References (21)

1. M. Sun, R. Thuret, and F. Abdollah Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis Eur Urol 59 2011 135 141
2. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
3. K.D. Courtney, and T.K. Choueiri Optimizing recent advances in metastatic renal cell carcinoma Curr Oncol Rep 11 2009 218 226
4. N.K. Janzen, H.L. Kim, R.A. Figlin, and A.S. Belldegrun Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852
5. T.K. Choueiri, A.P. Fay, and R. Gagnon The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma Clin Cancer Res 19 2013 5218 5226
6. B. Escudier, J. Bellmunt, and S. Negrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
7. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
8. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
9. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
10. R.J. Motzer, T.E. Hutson, and D. Cella Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
11. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
12. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
13. L.C. Harshman, W. Xie, and G.A. Bjarnason Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study Lancet Oncol 13 2012 927 935
14. B.C. Leibovich, J.C. Cheville, and C.M. Lohse A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials J Urol 174 2005 1759 1763
15. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
16. A.R. Golshayan, S. George, and D.Y. Heng Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy J Clin Oncol 27 2009 235 241
17. T.K. Choueiri, A. Plantade, and P. Elson Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
18. R.J. Motzer, J. Bacik, T. Mariani, P. Russo, M. Mazumdar, and V. Reuter Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology J Clin Oncol 20 2002 2376 2381
19. Molina AM, Lin X, Korytowsky B, et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer. In press.
20. E.J. Abel, S.H. Culp, N.M. Tannir, P. Tamboli, S.F. Matin, and C.G. Wood Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib Eur Urol 60 2011 1273 1279
21. V. Grünwald, D. Kalanovic, R. McKay, J. Perkins, R. Simantov, T.K. Choueiri, Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC). Paper presented at: 2013 European Cancer Congress.